These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 32654947)
1. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study. Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947 [TBL] [Abstract][Full Text] [Related]
2. Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker. Elsawy AA; Awadalla A; Abdullateef M; Ahmed AE; Abol-Enein H Urol Oncol; 2021 Jul; 39(7):437.e11-437.e19. PubMed ID: 33785220 [TBL] [Abstract][Full Text] [Related]
3. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526 [TBL] [Abstract][Full Text] [Related]
4. Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence. Kim DH; Choi MS; Choi JH; Lee C; Jeh SU; Kam SC; Hwa JS; Hyun JS; Choi SM Investig Clin Urol; 2024 May; 65(3):279-285. PubMed ID: 38714518 [TBL] [Abstract][Full Text] [Related]
5. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer. Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D; Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321 [TBL] [Abstract][Full Text] [Related]
7. Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-Risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary? Tadrist A; Gondran-Tellier B; McManus R; Al Balushi K; Akiki A; Gaillet S; Delaporte V; Karsenty G; Lechevallier E; Boissier R; Baboudjian M J Endourol; 2021 Jul; 35(7):1042-1046. PubMed ID: 33626963 [No Abstract] [Full Text] [Related]
8. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes. Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z Oncology; 2024; 102(4):337-342. PubMed ID: 37647883 [TBL] [Abstract][Full Text] [Related]
9. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer. Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924 [TBL] [Abstract][Full Text] [Related]
10. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience. Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376 [TBL] [Abstract][Full Text] [Related]
11. Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer. Fujita N; Hatakeyama S; Okita K; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C Urol Oncol; 2021 Jan; 39(1):75.e9-75.e16. PubMed ID: 32665123 [TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of tumor location in nonmuscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing Chinese multicenter and SEER registries. Liu L; Li K; Wang SG; Wang J; Yao Z; Xie Y; Ji Z; Chen Z; Hu H; Chen H; Hu J; Hou Y; Liu Z; Li Y; Ding Y; Kuang Y; Xun Y; Hu J; Zhang J; Li H; Chong T; Bi J; Wang Z; Wang Y; Zhang P; Wei Q; Chen Z; Li L; Huang J; Liu Z; Chen K; Int J Surg; 2024 Sep; 110(9):5641-5651. PubMed ID: 38788195 [TBL] [Abstract][Full Text] [Related]
13. Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer. Gondran-Tellier B; Abdallah R; Sichez PC; Akiki A; Toledano H; Gaillet S; Delaporte V; Karsenty G; Bastide C; Daniel L; Garcia S; Rossi D; Lechevallier E; Boissier R; Baboudjian M Prog Urol; 2021 May; 31(6):316-323. PubMed ID: 33663939 [TBL] [Abstract][Full Text] [Related]
14. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM; BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434 [TBL] [Abstract][Full Text] [Related]
15. Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study. Ślusarczyk A; Ismail H; Zapała Ł; Piecha T; Zapała P; Radziszewski P Ann Surg Oncol; 2024 Jul; 31(7):4773-4786. PubMed ID: 38570378 [TBL] [Abstract][Full Text] [Related]
16. Prospective non-randomized comparison of transurethral laser en bloc resection vs. conventional resection of bladder tumors larger than 3 cm. Petov V; Timofeeva E; Sukhanov R; Baniel J; Mustafin M; Fajkovic H; Morozov A; Teoh JY; Singla N; Laukhtina E; Herrmann TR; Shariat SF; Enikeev D Minerva Urol Nephrol; 2024 Aug; 76(4):436-441. PubMed ID: 39051891 [TBL] [Abstract][Full Text] [Related]
17. Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? Alsyouf M; Ladi-Seyedian SS; Konety B; Pohar K; Holzbeierlein JM; Kates M; Willard B; Taylor JM; Liao JC; Kaimakliotis HZ; Porten SP; Steinberg GD; Tyson MD; Lotan Y; Daneshmand S; Urol Oncol; 2023 Feb; 41(2):109.e9-109.e14. PubMed ID: 36435710 [TBL] [Abstract][Full Text] [Related]
18. Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design. Roumiguié M; Wong A; Belanger E; Wang G; Black PC Urol Oncol; 2023 May; 41(5):254.e9-254.e15. PubMed ID: 36566105 [TBL] [Abstract][Full Text] [Related]
19. Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial. Wong CH; Lim JY; Ko IC; Leung DK; Yuen SK; Yip SY; Ng CF; Teoh JY; Chan ES World J Urol; 2024 Aug; 42(1):466. PubMed ID: 39093420 [TBL] [Abstract][Full Text] [Related]
20. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]